Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment

Transfusion management in the era of magrolimab (Hu5F9‐G4), an anti‐CD47 monoclonal antibody therapy

“…Strategies for mitigation when interference is seen after magrolimab treatment: Use monoclonal anti‐human IgG that does not recognize IgG4 for antibody detection and serological cross‐matching 12,43,46 If monoclonal anti‐human IgG lacking IgG4 sensitivity fails, use multiple allogenic adsorptions with RBCs or platelets to remove magrolimab from patient plasma 12,43,46 . RBCs may be preferred given easier access compared with platelets.…”

“…12,43,46 • If monoclonal anti-human IgG lacking IgG4 sensitivity fails, use multiple allogenic adsorptions with RBCs or platelets to remove magrolimab from patient plasma. 12,43,46 RBCs may be preferred given easier access compared with platelets. Samples may need to be referred to a specialized center for testing.…”